Divi's Laboratories Limited (NSEI: DIVISLAB)
Health Care · Life Sciences Tools & Services · IN
Rs9,340.00
+0.98% today · +44.3% 1Y
Divi's Laboratories Limited (NSEI: DIVISLAB) operates in the Life Sciences Tools & Services industry within the Health Care sector. The company is valued at $25.62B and employs 11,565 people.
Over the last twelve months the share price has gained 44.3%, trading between 5.65K and 9.74K.
Tweenvest scores Divi's Laboratories Limited across four factors: quality 83/100, value 18/100, growth 66/100, dividend 23/100. Its strongest factor is quality.
DIVISLAB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $25.62B
- Revenue (TTM)
- $1.19B
- P/E
- 84.74
- EPS
- 110.21
- Dividend yield
- 0.32%
- Beta (5Y)
- 0.23
- 52-week high
- Rs9,740.00
- 52-week low
- Rs5,647.50
- Avg volume (3M)
- —
- Shares outstanding
- 265.47M
- Employees
- 11,565
- Next earnings
- —
About Divi's Laboratories Limited
Divi's Laboratories Limited, established in 1990 and based in Hyderabad, India, operates globally in the production and distribution of generic active pharmaceutical ingredients (APIs), intermediate chemicals, and nutraceuticals. The company's market footprint encompasses India, the United States, Asia, Europe, and other international regions. In addition to its core product lines, Divi's offers bespoke synthesis services for APIs and intermediates. It also provides a diverse range of carotenoids and markets various vitamins, catering to the nutritional, pharmaceutical, food and beverage, and animal feed industries. The firm was formerly known as Divi's Research Center before rebranding to Divi's Laboratories Limited in 1994.
- ISIN
- INE361B01024
- Founded
- 1990
- Listed since
- Mar 12, 2003
- Exchange
- National Stock Exchange of India
- Currency
- INR
Other Life Sciences Tools & Services companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Samsung Biologics Co.,Ltd.KOSE: A207940 | $41.93B | ₩1,219,000.00 | -9.97% |
| Mettler-Toledo International Inc.NYSE: MTD | $31.06B | $1,560.21 | +0.66% |
| WuXi Biologics (Cayman) Inc.SEHK: 2269 | $28.16B | HK$53.85 | -0.46% |
| West Pharmaceutical Services, Inc.NYSE: WST | $25.76B | $370.09 | +1.12% |
| Sartorius Stedim Biotech S.A.ENXTPA: DIM | $23.18B | €214.20 | +0.66% |
| Sartorius AktiengesellschaftXTRA: SRT3 | $17.70B | €254.30 | +0.51% |
| Revvity, Inc.NYSE: RVTY | $17.20B | $154.46 | +0.18% |
| Medpace Holdings, Inc.NasdaqGS: MEDP | $17.08B | $621.11 | +1.48% |
Figures last refreshed Oct 11, 2026.